Windtree Contracts Chinese Firm to Make Evofem's Contraceptive

Dow Jones
2025/06/27

By Dean Seal

Windtree Therapeutics said it has contracted with a pharmaceutical manufacturer in China to produce Evofem Biosciences's hormone-free contraceptive product Phexxi at a low cost.

The biotechnology company, Evofem's sourcing partner for Phexxi since March, said Thursday that the contract should cut Phexxi's manufacturing costs by over 50% by the end of 2026.

Windtree expects to start seeing some revenue from the arrangement next year.

Early-stage manufacturing is set to begin later this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 26, 2025 16:57 ET (20:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10